SHR-1316 Combined With Chemotherapy and Chest Radiotherapy in ES-SCLC

Phase 2 Unknown 67 enrolled Shandong Cancer Hospital and Institute

NaSingle-groupOpen-labelTreatment

Summary

This study is a one arm, open, single center phase II study. The main purpose of this study was to evaluate the tolerance and preliminary efficacy of SHR1316 combined with chest radiotherapy after induction therapy.

Timeline

Start: 2020-10-01
Primary completion: 2024-10
Completion: 2024-10

Publications

Chen D, Zou B, Li B, Gao A, Huang W, Shao Q, Meng X, Zhang P, Tang X, Hu X, Zhang Y, Guo J, Zhao C, Yuan J, Li Q, Zhu C, Yu J, Wang L. Adebrelimab plus chemotherapy and sequential thoracic radiotherapy as first-line therapy for extensive-stage small-cell lung cancer (ES-SCLC): a phase II trial. EClinicalMedicine. 2024 Aug 21;75:102795. doi: 10.1016/j.eclinm.2024.102795. eCollection 2024 Sep.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Adebrelimab	Monoclonal antibody	20 mg/kg	—
Subject	Carboplatin	Small molecule	5 unknown	Intravenous
Subject	Cisplatin	Other / unclassified	75 mg/m2	Intravenous
Subject	Etoposide	Small molecule	100 mg/m2	Intravenous

SHR-1316 Combined With Chemotherapy and Chest Radiotherapy in ES-SCLC

Summary

Timeline

Publications

Drugs

Indications